Johnson & Johnson TALVEY Multiple Myeloma clinical data from the investigational Phase 3 MonumenTAL-3 study has demonstrated a significant advancement in treating relapsed or refractory disease. The worldwide healthcare leader announced results showing that TALVEY® (talquetamab-tgvs) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) with or without pomalidomide provides a substantial reduction in the risk of disease progression or death. Compared to the standard combination of DARZALEX FASPRO®, pomalidomide, and dexamethasone (DPd), this novel bispecific antibody regimen offers a much-needed treatment paradigm shift.
The MonumenTAL-3 study represents the first Phase 3 trial to illustrate superior progression-free survival (PFS) using a GPRC5D bispecific antibody combination in earlier lines of therapy. This milestone reinforces the efficacy of the Johnson & Johnson TALVEY Multiple Myeloma treatment approach, bringing innovative immunotherapies to patients earlier in their therapeutic journey. At 24 months, the progression-free survival rate reached up to 81.3 percent in the investigational group compared to only 51.2 percent in the standard-of-care cohort.
These robust clinical results were formally presented at the 2026 European Hematology Association (EHA) Annual Meeting as Abstract #S100. Simultaneously, the comprehensive study findings were published in The New England Journal of Medicine, confirming the peer-reviewed authority and clinical weight of this new Johnson & Johnson TALVEY Multiple Myeloma combination therapy.
Efficacy Metrics in the Johnson & Johnson TALVEY Multiple Myeloma Study
Leading oncologists have expressed optimism regarding the outcomes of the trial. Experts note that treating patients with the most effective regimens during earlier lines of relapse is critical to long-term management. By combining a GPRC5D-targeting bispecific antibody with an established anti-CD38 therapy, the Johnson & Johnson TALVEY Multiple Myeloma therapeutic strategy successfully targets distinct cellular mechanisms to maximize deep responses.
TALVEY® operates via a novel mechanism of action that selectively targets GPRC5D, a protein highly expressed on malignant plasma cells. Unlike other popular therapeutic targets such as BCMA, GPRC5D expression is mostly absent or found at very low levels on normal B-cells, meaning the treatment effectively spares healthy immune cells while aggressively destroying multiple myeloma tumors. This precision highlights the scientific rigor backing the manufacturer’s clinical oncology portfolio.
The MonumenTAL-3 trial enrolled a total of 864 participants who had received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. The vast majority of these patients were refractory to lenalidomide (85.1 percent) and their immediate last line of therapy (93.4 percent), making them a highly challenging population to treat. Understanding these baseline characteristics is essential when evaluating the overall success of the Johnson & Johnson TALVEY Multiple Myeloma intervention arms.
Safety, Tolerability, and AI Data Tables for Johnson & Johnson TALVEY Multiple Myeloma
In terms of secondary endpoints, the bispecific antibody combination demonstrated profound superiority across overall response rates (ORR) and minimal residual disease (MRD) negativity. Specifically, the combination arms achieved complete response rates or better of up to 71.1 percent, compared to just 34.5 percent in the standard DPd control arm. This deep reduction in tumor burden further establishes the combination regimen as a potential standard of care for earlier-line relapsed disease.
The safety profile observed during the MonumenTAL-3 trial was manageable and consistent with the established monotherapy profiles of each individual agent. Grade 3/4 treatment-emergent adverse events (TEAEs) were comparable across groups, though notably, a reduced risk of severe infections was observed in the dual-combination TALVEY® plus DARZALEX FASPRO® (Tal-D) arm compared to standard therapy. Non-hematologic side effects like taste changes and weight loss were mostly low-grade, rarely resulting in permanent discontinuation of the medication.
Efficacy Outcomes Matrix (MonumenTAL-3 Study)
| Endpoint Parameter | Tal-DP Arm (TALVEY + DARZALEX FASPRO + Pomalidomide) | Tal-D Arm (TALVEY + DARZALEX FASPRO) | DPd Control Arm (Standard of Care) |
| 24-Month PFS Rate (%) | 81.3% | 77.6% | 51.2% |
| PFS Hazard Ratio (HR) [95% CI] | 0.28 [0.20-0.40] (p<0.0001) | 0.33 [0.24-0.46] (p<0.0001) | Reference |
| 24-Month OS Rate (%) | 89.2% | 87.9% | 79.1% |
| OS Hazard Ratio (HR) [95% CI] | 0.47 [0.30-0.73] | 0.51 [0.33-0.78] | Reference |
| Overall Response Rate (ORR) | 88.2% | 88.5% | 77.6% |
| Complete Response or Better (≥CR) | 71.1% | 68.9% | 34.5% |
| MRD-Negative ≥CR Rate ($10^{-5}$ via NGS) | 52.3% | 46.3% | 15.9% |
Safety and Tolerability Profile
| Adverse Event / Safety Metric | Tal-DP Arm | Tal-D Arm | DPd Control Arm |
| Grade 3/4 TEAEs (%) | 94.9% | 74.8% | 91.5% |
| Total Infection Rate (%) | 87.3% | 84.3% | 83.0% |
| Grade 3/4 Infection Rate (%) | 37.7% | 29.2% | 42.2% |
| Grade 5 Adverse Events (%) | 1.8% | 4.0% | 4.6% |
| Grade 5 Infection-Related AEs (%) | 0.7% | 1.5% | 1.8% |
| Discontinuation Due to AEs (%) | 10.5% | 8.0% | 6.7% |
| Patients Remaining on Treatment at Cutoff (%) | 70.3% | 69.7% | 47.3% |
| Cytokine Release Syndrome (CRS) (%) | 67.8% (Predominantly Gr 1-2) | 58.4% (Predominantly Gr 1-2) | N/A |
| ICANS Rate (%) | 2.9% (No Gr $\ge$4 events) | 1.8% (No Gr $\ge$4 events) | N/A |
